RHÖN-KLINIKUM AG

  • WKN: 704230
  • ISIN: DE0007042301
  • Land: Deutschland

Nachricht vom 11.03.2019 | 16:39

RHÖN-KLINIKUM AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

RHÖN-KLINIKUM AG

11.03.2019 / 16:39
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: RHÖN-KLINIKUM AG
Street: Salzburger Leite 1
Postal code: 97616
City: Bad Neustadt a.d.Saale
Germany
Legal Entity Identifier (LEI): 529900MVGMIVUDQY9E20

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
X Other reason:
Voluntary group communication only at subsidiary level

3. Details of person subject to the notification obligation
Natural person (first name, surname): Ilona Braun
Date of birth: 02 Apr 1950

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
B. Braun Melsungen AG

5. Date on which threshold was crossed or reached:
12 Dec 2018

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 25.23 % 0.00 % 25.23 % 66,962,470
Previous notification 25.23 % 0.00 % 25.23 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE0007042301 16895625 % 25.23 %
Total 16895625 25.23 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
%
    Total %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
Ilona Braun % % %
BraHo Verwaltungsgesellschaft mbH % % %
B. Braun Holding GmbH & Co. KG % % %
B. Braun Familienholding Verwaltungs SE % % %
B. Braun Familienholding SE & Co. KG % % %
B. Braun SE % % %
B. Braun Melsungen Aktiengesellschaft 25.23 % % 25.23 %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
11 March 2019



11.03.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Hohes Ergebnis für Q3/2019

18. Oktober 2019, 10:40

Aktuelle Research-Studie

Ahlers AG

Original-Research: Ahlers AG (von GSC Research GmbH): Kaufen

18. Oktober 2019